Targets › GAS6
1 program from 1 company in 1 trial: 1 Phase 1; Oncology.
Ligand for tyrosine-protein kinase receptors AXL, TYRO3 and MER whose signaling is implicated in cell growth and survival, cell adhesion and cell migration. GAS6/AXL signaling plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone…. (UniProt, Q14393)
Open in Phaseline: the race on GAS6, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Oklahoma | Batiraxcept Growth arrest-specific protein 6 inhibitor | GAS6 | Phase 1 | Urothelial Carcinoma | – |
Urothelial Carcinoma (1)
mixed (1)
University of Oklahoma (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.